GlassScriptPhysician profile
David R Morawski
NPI 1215917257
$64,348.34
in general payments reported to CMS, 2019-2025
16 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $14K · 2021: $17K · 2022: $1,046 · 2023: $18K · 2024: $11K · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $11K · Travel and Lodging: $4,846 · Royalty Or License: $1,808 · Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,875.00 |
| Consulting Fee | $10,887.50 |
| Travel and Lodging | $4,846.19 |
| Royalty Or License | $1,808.27 |
| Food and Beverage | $1,444.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $63,662.09 | 2019-2025 | Legacy Stelkast Knee, Excelsiusgps Robotic Navigation System, Onvoy |
| Pacira Pharmaceuticals Incorporated | $142.37 | 2021-2025 | Exparel, Iovera, Zilretta |
| Depuy Synthes Sales INC. | $133.44 | 2020-2024 | Velys |
| Pacira Therapeutics, INC. | $59.95 | 2020 | |
| Smith+Nephew, INC. | $53.42 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $49.44 | 2025 | |
| Stryker Corporation | $41.76 | 2025 | T2 Alpha |
| Ethicon US, LLC | $32.72 | 2024 | Stratafix |
| Zimvie INC. | $31.64 | 2023 | |
| Solventum Corporation | $31.57 | 2025 | Prevena |
| Innovation Technologies INC | $24.26 | 2024 | Irrisept |
| Microport Orthopedics INC | $23.20 | 2022 | |
| Baudax Bio INC. | $21.61 | 2022 | |
| Intellijoint Surgical INC. | $20.52 | 2021 | |
| Heron Therapeutics, INC. | $20.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$365,806.19 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morawski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.